Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Nervgen Pharma's Competitiveness

Name: Nervgen Pharma Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Nervgen Pharma (NGEN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2025

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/NGEN/competitors                    

                        https://api.csimarket.com/api/v1/companies/NGEN/relationships                    

                        https://api.csimarket.com/api/v1/companies/NGEN/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Nervgen Pharma's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Nervgen Pharma Corp	-	-	-	-
Similar-Size Competitors (9)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

NGEN Stock Performance relative to its Competitors

NGEN Competitors (weighted) Percent change over the selected range

Nervgen Pharma's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

Similar-Size
(0 of 7)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Nervgen Pharma Corp	-30.30 %	Underperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (0)	40.4%	63.2%
Similar-Size Competitors (7)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Nervgen Pharma's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

NGEN Stock Performance relative to Similar-Size Competitors

NGEN Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Nervgen Pharma's Comment on Competition and Industry Peers

The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapid technological advancement, intense competition, and strong intellectual property protection. Competitors may develop and market technologies or products more quickly, effectively, safely, or cost-efficiently than the company's product candidates, potentially affecting commercial opportunities. Competitors are developing or may develop products, product candidates, and processes that compete with the company's product candidates. Enrollment in clinical trials may be influenced by competitors conducting trials for product candidates targeting the same indications, which could divert eligible subjects. Currently, no approved pharmaceutical products provide sustained functional improvements for individuals with spinal cord injury (SCI), although mobility assistance and neuro-related therapies are available.

Competitor data is not yet available for Nervgen Pharma.